Thread by @OncBrothers

#WCLC22 Highlights #CommunityOncology perspective:

1. #YESS Study - @RachM_UoN

2. #IMPower010 Update

3. #CALGB140503 - Sublobar resection

4. #SHAWL Study - @NarjustFlorezMD @jillfeldman4

5. #NADIM2 Trial by @MARIANOPROVENCI

1/6

#LCSM #MedTwitter @OncoAlert #OncEd @IASLC

1. #YESS Study @RachM_UoN: Lung CA screening with smoking cessation intervention concurrently:

- Smoking cessation is one of the most effective way to reduce lung CA mortality
- 33% quit at 3 months
- Women more likely to benefit

2/6

2. #IMPower010 Update: Atezo has been approved for adjuvant NSCLC, Stg II - IIIA post surgery and chemo.

- mFU: 46mos
- OS trend for stage II-IIIA PDL1≥1% (HR 0.71)
- BUT, meaningful OS with PDL1≥50% (HR 0.42)

3/6

3. #CALGB140503: Ph3, Sublobar resection vs. lobectomy for T1aN0 ≤2 cm, N = 687

- Sublobar resection was non-inferior (new SOC)
- Similar PFS and OS
- 30.4% recurrence with Sublobar vs 29.3% recurrence with lobar resections

4/6

4. #SHAWL Study: Sexual Health Assessment in Women with Lung Cancer by @NarjustFlorezMD @jillfeldman4 @GO2Foundation

- Up to 95% Lung CA pts score below 50th percentile
- 77% Lung CA pts have moderate-severe sexual dysfunction
- Integrate sexual health with each visit

5/6

5. #NADIM2 Trial by @MARIANOPROVENCI: neoadj chemo-IO in stage III NSCLC

- Improved PFS (HR 0.48) & OS (HR 0.40)
- Improved surgical outcomes (92% with R0 resection)

6/6